The second step in vitro trial of Ankaferd® Bloodstopper®:comparison with other hemostatic agents

Aim: To investigate the efficacy of Ankaferd Bloodstopper (ABS) and compare ABS with the other hemostatic agents stillused in urologic surgery.Materials and methods: Forty Wistar rats were divided into 5 groups: Group T (traditional), partial nephrectomy (PN)with hilar control as per the conventional technique; Group G (Glubran 2), conventional PN followed by the application of Glubran 2; Group F (FloSeal), FloSeal application to the resected area of the kidney; Group C (Celox), Celox was applied; Group A (ABS), Ankaferd was used. Warm ischemia time (WIT) and hemostasis time (HT) were recorded and histopathologic features were compared among the groups. Results: In Group A, a significant decrease in WIT was detected while the difference was significant (P 0.001). Statistic alanalysis confirmed that the evaluation of HT (in seconds) returned similar results to those seen in WITs among allgroups. In Group A, decreased HT was confirmed in comparison to Group T while HT increased in comparison to theother groups (G, C, and F) (P 0.001). Increased fibrosis and adhesion were shown in Group F while significant erythrocyte aggregation and microvascular proliferation were observed in Groups G, F, and A (P 0.001).Conclusion: A novel hemostatic agent, ABS, is as effective as other licensed hemostatic agents with comparable WIT and HT and better results in terms of histopathologic findings.